Disclosure Quality

Disclosure Quality

Doximity's reported cash is real: operating cash flow has run 1.2 to 1.7 times net income for five straight years, and the classic forensic tests for manufactured earnings come back clean. The reliability questions sit one layer in — roughly one-seventh of pretax profit is fading treasury income, the prior-year record was flattered by a low tax rate, and the engagement metrics and module revenue that carry the growth story are, by management's own account to the SEC, undefined and unallocable.

The cash is real

The first thing a skeptic checks is whether reported profit turns into cash. Here it does, and then some. Operating cash flow was $326.5 million in fiscal 2026 against $196.1 million of net income — a 1.67x conversion — and the ratio has exceeded 1.0 in every year since fiscal 2023 [1]. The mechanism is ordinary for a subscription business: customers pay ahead of the service, so cash arrives before revenue is booked, and two large non-cash charges — $121.6 million of stock-based compensation and $14.4 million of depreciation and amortization — sit between accounting profit and cash [2]. Capital expenditure is close to zero; the company even routes its modest internal-software build through the investing line rather than capitalizing costs that belong in operating expense.

Source: FY2026 10-K, Consolidated Statements of Cash Flows and Statements of Operations [3] [4]. Fiscal 2022 net income exceeds cash flow because of a one-time $40.8 million tax benefit that year.

The supporting checks agree. Days sales outstanding has held near 82 days across fiscal 2024 to 2026, and receivables grew 12.8% in fiscal 2026 against 13.0% revenue growth — no build-up that would signal revenue booked ahead of collection [5]. Goodwill and intangibles together are 10.7% of total assets and have never been impaired, so there is no soft-asset overhang waiting to be written down. The allowance for doubtful accounts is a stable 0.9% of receivables against a customer base of large pharmaceutical manufacturers and health systems.

Source: derived from FY2026 10-K balance sheet, income statement and cash flow statement, fiscal 2024–2026 [6] [7].

That cash generation still carries the two caveats earlier chapters priced. The largest cash add-back, stock-based compensation, is a real economic cost paid to employees in shares rather than dollars; the gap between reported free cash flow and owner cash flow after that charge is the subject of Margin of Safety. And the one working-capital line worth watching turned negative this year: deferred revenue fell $8.1 million in fiscal 2026 after rising $15.2 million in fiscal 2025, which management attributes to the timing of customer billings and program launches [8]. Because deferred revenue is billings not yet recognized, a drawdown means revenue ran slightly ahead of new bookings — a modest forward-looking signal that fits the roughly 4% growth guided for fiscal 2027, not a sign of inflated current earnings.

What the headline profit contains

The reliability question that reported cash does not answer is what sits inside net income. Two items make the profit line less representative of the operating business than it looks.

The first is interest income. Doximity holds $748.6 million of cash and marketable securities, and the yield on it — $35.7 million in fiscal 2026 — is booked below the operating line as "other income" [9]. That is 14% of pretax income, up from 12% two years ago as rising rates lifted the yield. It is genuine cash, but it is a treasury return, not a return on the physician-marketing franchise, and it is set to shrink: the investment base fell 18% over the year as buybacks drew it down, and the 10-K warns that future investment income may fall short as rates ease [10].

The second is the tax rate. Fiscal 2025's $223.2 million of net income — the "record" year the current price is measured against — carried a 15.3% effective tax rate; fiscal 2026 normalized to 21.6% [11]. That single change explains more than half of the 12% drop in reported net income: pretax income fell $13.6 million while the tax provision rose $13.6 million. Operating income itself fell a milder 5.7%. Across the mix, fiscal 2026's earnings decline overstates the operating slowdown, and fiscal 2025's peak overstates the underlying earning power — the reverse-signal a reader anchoring on the price-to-earnings multiple should carry.

Source: FY2026 10-K, MD and A Results of Operations and Note 16 [12] [13].

The non-GAAP framing management prefers cuts the opposite way. Adjusted EBITDA of $357.8 million (a 55% margin) removes the $35.1 million of other income — so it strips out the treasury tailwind — but it also adds back the $121.6 million of stock-based compensation, this year plus new $4.9 million legal and $1.6 million acquisition adjustments [14]. The reported record is honest on both counts; the point is that neither headline — GAAP net income nor adjusted EBITDA — is a clean read of operating economics on its own.

The metrics the story runs on

The financial statements are the reliable part of Doximity's disclosure. The softer part is the operating data the growth and AI narratives lean on — and here a fiscal 2026 SEC review put the questions on the record. The Division of Corporation Finance's February 23, 2026 comment letter asked Doximity to define and quantify the active-user engagement metrics its executives cite on earnings calls but that appear nowhere in the MD and A, to clarify the denominator behind the "more than 80% of U.S. physicians" claim, and to disaggregate revenue by product module — noting the module data appeared "readily available" [15] [16]. Doximity's March 23 response, and the staff's March 26 closeout, are what make the exchange informative.

Source: SEC comment letter (Feb 23, 2026) and Doximity response (Mar 23, 2026) [17] [18].

Two of the responses are the substance. On engagement, management told the staff that the active-user figures referenced on calls "do not correlate highly with its subscription revenue," were mostly cited qualitatively in response to analyst questions, and that it "does not plan on disclosing other user engagement metrics on earnings calls on a go-forward basis" [19]. That is a notable concession: the record-engagement figures offered elsewhere as evidence the platform is deepening are, by the company's own account, not a reliable proxy for the revenue they are meant to foreshadow, and they are being retired from the earnings script rather than defined and standardized. On revenue mix, management stated it "does not track or manage revenue at the individual module level, and its financial systems do not have the capability to identify or allocate revenue by module" — even though its CEO had called Newsfeed the "most monetized" product [20]. Integrated subscriptions bundle several modules under a single stand-ready obligation, so revenue is recognized at the subscription level. The consequence for an investor is concrete: there is no way from the filings to see how revenue splits across products, and no way to isolate AI Search revenue as it appears — it will surface, if it does, inside the same undifferentiated Marketing Solutions line.

Read against the ownership structure set out in Founder Control, the concession sharpens into a governance point. Doximity is controlled by an insider group holding 80.3% of the votes on 31.3% of the economics (the founder alone 76.3% on 28.9%), and in a February-March 2026 exchange with the SEC that same company conceded that the active-user engagement metrics its executives cite do not correlate highly with subscription revenue — and will be dropped from earnings calls — and that its systems cannot identify or allocate revenue by module. [21] [22] A minority holder can therefore neither outvote the insider block — the super-voting shares do not auto-convert to one-share-one-vote until 2031 — nor independently check the two primary non-financial inputs to the operating story, the engagement KPIs and the module-level revenue split.

The counter-fact runs the other way, and it matters. This was a routine disclosure-improvement review, not an enforcement action; the staff completed it with no further comment on March 26, 2026 [23]. And the review produced real improvements: beginning with the fiscal 2026 10-K, Doximity will define its workflow-provider metric with a prior-year comparable and pin down the physician denominator — physicians under 76, holding an active license, listed on the NPI registry, who have claimed a profile [24]. Disclosure is getting better, not worse. What does not improve is module-level revenue visibility, which management has declined to provide.

Two adjacent facts round out the picture. Fiscal 2026 was the first year a single customer crossed 10% of revenue — one customer at 11%, against no customer above the threshold in fiscal 2025 or 2024 — a concentration worth tracking in a business already reliant on a small set of large pharmaceutical buyers [25] [26]. And the same metric family the SEC questioned was the subject of a securities class action over "disclosures regarding user count and engagement rates," settled in December 2025 for $31 million paid entirely by insurers with no admission of liability; six shareholder derivative suits remain outstanding, with loss not estimable — detail covered in The AI Contest [27].

The read that fits the evidence: the audited numbers Doximity reports are high quality and cash-backed, and there is no sign of manufactured earnings. The reliability gap is in the operating metrics and revenue mix that sit outside the audited statements — the very inputs the growth-and-AI case relies on — where the company has now conceded the KPIs do not track revenue and the module split cannot be produced. That does not impeach the cash; it means the story the cash is supposed to be growing into has to be taken partly on trust. The condition that would change the read is a fiscal 2027 in which a defined workflow-engagement metric moves with reported revenue, and AI Search revenue becomes visible enough to verify — the disclosures management has now promised are the place to check.